Truist raised the firm's price target on Progyny to $33 from $30 and keeps a Buy rating on the shares after hosting meetings with its management team. The key message from these meetings was that the company remains a highly differentiated fertility benefits platform, built around superior clinical outcomes, comprehensive member support, and deep provider network management, the analyst tells investors in a research note.
